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1082Stent ThrombosisA Clinical PerspectiveABSTRACTThe invention of intracoronary stents greatly increased the safety and applicability of percutaneous coronary inter-
ventions. At this time, >1 million coronary stent implantations are performed each year in the United States. But
together with the growing use of stents, stent thrombosis, the most feared complication after stent implantation,
has emerged as an important entity to understand and prevent. Adjunct pharmacological therapy, stent design,
and deployment technique have been adjusted ever since to reduce its occurrence. The current clinical overview
of stent thrombosis ranges from its pathophysiology to current state-of-the-art technical and pharmacological
recommendations to avoid this complication. (J Am Coll Cardiol Intv 2014;7:1081–92) © 2014 by the American
College of Cardiology Foundation.T he safety and efﬁcacy of percutaneous coro-nary intervention (PCI) improved dramati-cally after the introduction of the coronary
artery stent. A severe and common early complica-
tion of balloon angioplasty alone was abrupt
vessel closure, which was associated with signiﬁ-
cant morbidity and mortality and the need for
emergency coronary artery bypass surgery (1). Coro-
nary artery stents signiﬁcantly reduced the inci-
dence of abrupt vessel closure and also reduced
restenosis by essentially eliminating arterial re-
coil and negative remodeling after angioplasty (2).
From the very beginning, thrombosis of the metal
endoprosthesis, or stent thrombosis (ST), was recog-
nized as an important complication and adjunct
pharmacological therapy, and stent technique and
technology have been adjusted to reduce its
occurrence.
DEFINITION OF STENT THROMBOSIS
The sensitivity and speciﬁcity of the deﬁnition of
ST depends on the level of certainty required (a better
judgment can be made in the presence of angiography
or autopsy studies), but also on the accuracy of data
available during adjudication (e.g., events occurring
in remote locations and long after the index pro-
cedure cannot be easily adjudicated due to many
coinciding factors, interval interventions, and other
clinical conditions treated by unrelated medical
teams). Until 2007, a large variety of ST deﬁnitions
were in use, limiting the possibility to consistently
evaluate ST rates among studies. A standardized
deﬁnition of ST was proposed by the Academic
Research Consortium (ARC) (Table 1) (3). The ARC
deﬁnition acknowledges these issues by establishinga gradation of certainty (deﬁnite, probable, and
possible ST), and standardized the timing of ST
(acute, subacute, late, and very late ST), which may
have different pathophysiological mechanisms and
clinical implications.
SCOPE OF THE PROBLEM
At the very beginning of intracoronary stenting, with
low-pressure inﬂation and single-antiplatelet therapy,
bare-metal stents (BMS) were associated with high
rates of ST, ranging from 20% in early reports (4–6)
to around 3% to 5% (2,7) with the use of aggressive
anticoagulation therapy, which in turn was associated
with hemorrhagic complications. Colombo et al. (8)
ﬁrst introduced stenting with dual-antiplatelet
therapy (DAPT) instead of warfarin, accomplished
by attaining adequate stent expansion using
high-pressure balloon inﬂation. This implantation
technique achieved an acceptable 1.6% rate of angio-
graphically documented ST at 6-month follow-up and
was universally accepted from then on (9,10).
The incidence of ST up to 1 year follow-up seems
similar for DES and BMS and ranges from 0.6% to
3.2% for BMS and 0.6% to 3.4% for DES, depending
on patient and lesion characteristics (11–14). Before
the introduction of DES, ST was perceived as a com-
plication occurring early after stent implantation. In
2004, McFadden et al. (15) described 4 cases of late
and very late ST in ﬁrst-generation DES (sirolimus-
eluting stent, Cypher, Cordis, Warren, New Jersey,
and paclitaxel-eluting stent, Taxus, Boston Scientiﬁc,
Natick, Massachusetts). Subsequently, data from a
large all-comers registry suggested that very late ST
may occur steadily at an annual rate of 0.4% to 0.6%
after ﬁrst-generation DES implantation (16). These
TABLE 1 Deﬁnition of Stent Thrombosis According to the Valve
Academic Research Consortium
Level of Certainty Timing
Deﬁnite Early
Angiographic or pathological conﬁrmation of
partial or total thrombotic occlusion
within the peri-stent region
Acute (<24 h)








Any unexplained death <30 days of stent
implantation
31 days to 1 yr
Any myocardial infarction related to
documented acute ischemia in the
territory of the implanted stent
without angiographic conﬁrmation of
stent thrombosis and in the absence
of any other obvious cause
Possible Very Late
Any unexplained death beyond 30 days >1 yr
AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
ARC = Academic Research
Consortium
BMS = bare-metal stent(s)
DAPT = dual-antiplatelet
therapy
DES = drug-eluting stent(s)




OCT = optical coherence
tomography
PCI = percutaneous coronary
intervention
ST = stent thrombosis
STEMI = ST-segment elevation
ardial infarction
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1083reports also led to the recognition of the possibility of
late or very late ST with BMS when the randomized
trial results were systematically reviewed for both
stent types (17). Of note, all studies planned before
the adoption of the ARC ST deﬁnitions in 2007 did
not include any prospective mechanism for identiﬁ-
cation, tracking, and reporting late and very late ST
events and used diverse ST deﬁnitions. In recent
years, a new problem of recurrent ST has been
recognized. High rates of recurrent ST have been
published ranging from 5.9% to 18.8% (18–21).
CLINICAL PRESENTATION, DIAGNOSIS, AND
CLINICAL OUTCOME OF STENT THROMBOSIS
The typical clinical presentation of ST consists of
chest pain and ischemic electrocardiographic changes
in the target vessel territory. However, ST can also
present as sudden death, or it can be asymptomatic
in the setting of collateral vessels. The cornerstone
of the angiographic detection of thrombus is the
presence of a ﬁlling defect. When a ﬁlling defect is
detected angiographically, intravascular ultrasound
(IVUS) may be used to detect the underlying me-
chanism of ST (e.g., underexpansion, malapposition,
edge dissection) (22). Moreover, optical coherence
tomography (OCT) is very suitable for visualization
of the stent surface thanks to its high resolution
(10 mm), and its ability to detect the presence of
(sub) clinical thrombus has been experimentally
conﬁrmed (23).Table 2 shows published data on mortality
after ST (16,18–21,24–34). There is consider-
able variation in mortality after ST between
different studies, ranging from 11% to 42%. A
number of mechanisms may explain the high
mortality observed after ST. For example, in
patients who underwent stent implantation
for acute coronary syndrome (ACS) in-
dications in whom preexisting ischemic pre-
conditioning is undone by restoration of
adequate antegrade ﬂow, early ST may be
particularly harmful. Moreover, a study
comparing patients undergoing primary
PCI for ST-segment elevation myocardial
infarction (STEMI) due to de novo coronary
thrombosis with ST reported lower rates of
successful reperfusion in the ST group (93.9%
vs. 80.4%, p < 0.0001) (26).
PATHOPHYSIOLOGY OF ST. A multitude of
mechanisms lead to the occurrence of ST.
Many patient-related, lesion-related, procedural, and
post-procedural factors are associated with ST
(Table 3) (19,21,22,29,30,32,35–37). These predispose
to ST by one of the following pathophysiological
mechanisms: 1) exposure of blood before re-
endothelialization to prothrombotic subendothelial
constituents, stent struts, and/or polymer material
leading to activation of the extrinsic pathway of the
coagulation cascade; 2) persistent slow coronary
blood ﬂow and low shear stress leading to activation
of the intrinsic pathway; 3) inadequate pharmaco-
logical suppression of platelet activation (e.g., after
premature discontinuation of DAPT); and 4) the
presence of a systemic prothrombotic state (e.g., due
to ACS or malignancy). A large-scale meta-analysis
including 221,066 patients and 4,276 ST events found
that the most consistently reported predictors are
early DAPT discontinuation, the extent of coronary
artery disease, and total stent length (36).
EARLY ST. Early ST occurs within 30 days after stent
implantation, when technical and procedural factors
are important. A suboptimal procedural result (e.g.
slow ﬂow, inadequate post-procedural lumen di-
mensions, residual dissection, and tissue prolapse) is
associated with the incidence of early ST (19,37,38).
Because the arterial segment receiving the endo-
prosthesis has not yet re-endothelialized, inhibition
of platelet activation is a key factor: discontinuation
of DAPT during this time frame can be catastrophic
and provoke ST. Stenting in prothrombotic conditions
in patients with ACS is also strongly associated with
early ST (36). Due to its fast elimination at a time
that antiplatelet drugs may not yet have become
myoc
TABLE 2 Mortality After Stent Thrombosis
First Author (Ref. #) Year N Stent Type VARC Deﬁned? Timing of ST Follow-Up Mortality, %
Cutlip et al. (30) 2001 53 BMS No Early 6 months 20.8
Wenaweser et al. (20) 2005 95 BMS No Early and late 6 months 11.0
Iakovou et al. (29) 2005 49 DES, BMS No Early and late Not speciﬁed 45.0
Ong et al. (27) 2005 26 DES No Early 30 days 12.0
Kuchulakanti et al. (28) 2006 38 DES No Early and late 6 months 29.0
Daemen et al. (16) 2007 152 DES No Early and (very) late 6 months 11.0
de la Torre-Hernandez
et al. (32)
2008 301 DES, BMS No Early and (very) late Median 11.8 months 16.0
Aoki et al. (33) 2009 48 DES Yes, deﬁnite/probable Early 30 days 27.1
Chechi et al. (26) 2008 82 BMS Yes, deﬁnite Early and (very) late 6 months 20.9
van Werkum et al. (19) 2009 431 DES Yes, deﬁnite Early and (very) late Median 27.1 months 15.4
Lasala et al. (25) 2009 184 PES Yes, deﬁnite/probable Early and (very) late 7 days 23.4
Acute (n ¼ 17) 29.4
Subacute (n ¼ 60) 41.7
Late (n ¼ 51) 11.8
Very late (n ¼ 56) 12.5
Kimura et al. (31) 2009 71 SES Yes, deﬁnite Early and (very) late 30 days 20.4
Early (n ¼ 36) 11.0
Late (n ¼ 21) 38.0
Very late (n ¼ 14) 18.0
Kimura et al. (21) 2010 611 SES Yes, deﬁnite Early and (very) late 1 yr 25.0
Early (n ¼ 322) 25.0
Late (n ¼ 105) 27.8
Very late (n ¼ 184) 23.3
Moon et al. (18) 2010 31 DES, BMS Yes, deﬁnite Early and (very) late Median 34.9 months 14.3
Ergelen et al. (24) 2010 118 DES, BMS Yes, deﬁnite Early and (very) late Mean 22 months 17.4
Dangas et al. (34) 2012 156 DES Yes, deﬁnite/probable Early and (very) late 3 yrs 16.7
In-hospital 27.8
Out-of-hospital 10.8
Armstrong et al. (87) 2012 1,391 BMS, DES No Early In-hospital 7.9
1,370 Late In-hospital 3.8
4,318 Very late In-hospital 3.6
BMS ¼ bare-metal stent(s); DES ¼ drug-eluting stent(s); PES ¼ paclitaxel-eluting stent(s); ST ¼ stent thrombosis; VARC ¼ Valve Academic Research Consortium.
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1084effective, bivalirudin use in primary PCI may predis-
pose to acute ST compared with heparin plus optional
glycoprotein IIb/IIIa inhibitors (GPIs) (39,40).
LATE AND VERY LATE ST. Delayed endothelial
coverage, persistent ﬁbrin deposition, and ongoing
vessel inﬂammation are associated with ST >30 days
after stent implantation. Re-endothelialization after
stent implantation is signiﬁcantly delayed in DES
compared with BMS and is likely responsible for
the higher rates of very late ST with ﬁrst-generation
DES (41). Stent malapposition is deﬁned as lack of
contact between stent struts and the underlying
arterial wall intima (despite full stent expansion at
its nominal diameter). Late stent malapposition is
typically the result of positive vessel wall remodeling
(i.e., outward arterial wall expansion “away” from
the stent struts that were well apposed at the time
of implantation), appears more commonly in DEScompared with BMS, and has been associated with
(very) late ST (Figure 1) (42). Finally, neoathero-
sclerotic plaques can develop in neointima within
previously stented areas, which may rupture, causing
ST (Figure 2) (43). Neoatherosclerotic plaques have
been observed in both BMS and DES. However, path-
ological evidence suggests that neoatherosclerosis
may develop earlier in DES (44,45). Its development
appears to be similar in ﬁrst- and second-generation
DES (46).PHARMACOPREVENTION
P2Y12 INHIBITORS. The ISAR (Intracoronary Stenting
and Antithrombotic Regimen) and STARS (STent An-
ticoagulation RestenosiS) trials established DAPT
with aspirin and a thienopyridine as the stan-
dard of care after coronary stenting (9,10). In the
TABLE 3 Predictors of Early and (Very) Late Stent Thrombosis
Early Stent Thrombosis (Very) Late Stent Thrombosis
Patient Malignancy, heart failure, peripheral artery disease, diabetes mellitus,
acute coronary syndromes, nonadherence to dual-antiplatelet
therapy, genetic polymorphisms, thrombocytosis
End-stage renal disease, smoking, STEMI, nonadherence
to dual-antiplatelet therapy (unknown for very
late ST)
Lesion Bifurcation lesion, LAD, vessel size, lesion length, thrombus,
saphenous vein grafts
LAD, incomplete endothelialization, delayed healing,
previous brachytherapy, vein graft stenting
Procedural Stent undersizing, stent underexpansion, stent malapposition,
dissection, no pre-procedural thienopyridine administration,
bivalirudin as anticoagulant in STEMI patients, stent length
DES (compared with BMS), permanent polymer
DES (compared with bioresorbable polymer DES),
overlapping DES
Post-procedural Discontinuation of antiplatelet therapy Discontinuation of antiplatelet therapy (unknown for
very late ST), late acquired stent malapposition
LAD ¼ left anterior descending; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Table 2.
FIGURE 1 Stent Malapposition Detected by Intracoronary OCT Imaging
(Top) The axial image shows an OCT catheter in the center of the right cor-
onary artery. At the 2-o’clock position, bright, reﬂective stent struts are
visualized and are not in contact with the intima of the artery (blue dotted
arrow). There is a gap ofw0.6 mm between these stent struts and the artery.
This ﬁnding indicates stent malapposition, a mechanical, stent-based risk
factor for late stent thrombosis. (Bottom) The axial cross section was ob-
tained at w22 mm into an automated OCT pullback during contrast injection
to displace obscuring blood. OCT ¼ optical coherence tomography.
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1085STARS trial, treatment with aspirin and ticlopidine
compared with aspirin alone or a combination of
aspirin and warfarin reduced ST at 30 days (0.5% vs.
3.6% vs. 2.7%, p < 0.01). Subsequent clinical trials
showed that clopidogrel compared with ticlopidine
resulted in similar 30-day ST rates (47–49). Clopi-
dogrel, which was better tolerated and offered once-
daily dosing, subsequently replaced ticlopidine in
clinical practice.
CLOPIDOGREL. Clopidogrel is a prodrug; its active
metabolite irreversibly inhibits the P2Y12-type plate-
let adenosine diphosphate receptor (50). Genetic
variations in the activity of cytochrome enzymes
involved in metabolizing clopidogrel are associated
with lower plasma concentrations of active metabo-
lites and poor responder status. High on-treatment
platelet reactivity in patients receiving DAPT con-
sisting of aspirin and clopidogrel has been linked to
the occurrence of ST (51). New P2Y12 inhibitors have
been developed to address these limitations.
NEW P2Y12 INHIBITORS. Prasugrel, a thienopyridine,
inhibits platelet activation more rapidly, more con-
sistently, and to a greater intensity than clopidogrel
(52). Ticagrelor and cangrelor are nonthienopyridine
direct-acting, reversible, P2Y12 inhibitors. Of note,
cangrelor is an intravenous agent developed to be
used during PCI and reduces intraprocedural ST
compared with clopidogrel (53). Table 4 summarizes
trials investigating novel P2Y12 inhibitors compared
with clopidogrel and another trial that investigated
double-dose (150 mg) compared with standard-dose
(75 mg) clopidogrel in patients undergoing PCI for
ACS (53–57). Table 4 illustrates that double-dose clo-
pidogrel and novel P2Y12 inhibitors are associated
with lower rates of ST, but also with increased bleeding
rates. Speciﬁc subgroups including patients with
active pathological bleeding and previous stroke or
transient ischemic accident sustain an increasedbleeding risk, and prasugel is particularly contra-
indicated (54). In contrast, subgroups with pro-
thrombotic potential such as patients with diabetes
or acute myocardial infarction undergoing PCI may
derive greater net beneﬁt with prasugrel (58,59). The
signiﬁcant beneﬁt in cardiovascular survival docu-
mented with ticagrelor in addition to lower ST has
raised the possibility of pleiotropic effects (55).
FIGURE 2 Neoatherosclerosis as a Cause of Very Late Stent Thrombosis
of a DES Placed in an SVG
Three years after DES placement to the distal body of an SVG to the right coronary artery,
this patient presented with unstable angina. SVG angiography revealed a severe, hazy-
ﬁlling defect in the SVG stent. He was placed on intravenous heparin. The following day,
OCT of the SVG was performed. Two sequential OCT frames are presented with full and
magniﬁed images (dotted white box regions). (Top) OCT of the stent reveals mild neo-
intima within the stent, but at the 4-o’clock position, there is evidence of cap disruption
and a residual crater (white arrowhead, magniﬁed image). (Bottom) In the adjacent OCT
frame, the same region at the 4-o’clock position demonstrates an irregular contour
consistent with thrombus within the stent. Stent struts are noted covered by neointima
(small arrowheads at the 2-o’clock position). These ﬁndings indicate plaque rupture of
neoatherosclerosis within a stent, a recently appreciated mechanism of stent thrombosis.
DES ¼ drug-eluting stent(s); OCT ¼ optical coherence tomography; SVG ¼ saphenous vein
graft.
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1086ANTIPLATELET THERAPY IN PATIENTS ON ORAL
ANTICOAGULANTS. The WOEST (What is the Optimal
antiplatElet & Anticoagulant Therapy in Patients
with Oral Anticoagulation and Coronary StenTing)
study recently reported on the optimal antiplatelet
strategy after elective PCI with stent implantation in
patients with an indication for long-term treatment
with oral anticoagulants (60). A regimen consisting of
12 months of double therapy (oral anticoagulants
plus clopidogrel) was superior to triple therapy (oral
anticoagulants plus aspirin and clopidogrel) interms of bleeding and all-cause mortality at 1-year
follow-up. No difference in the incidence of ST was
noted between the study groups.
DURATION OF DAPT. Current American College of
Cardiology/American Heart Association guidelines
state a Class I, Level of Evidence: B recommendation
to continue DAPT for 12 months in patients receiving
a stent (BMS or DES) (61). DAPT for patients who
receive a stent for ACS indications may include pra-
sugrel 10 mg/day (a 5-mg daily dose may be given to
patients at high risk of bleeding), ticagrelor 90 mg
twice daily, or clopidogrel 75 mg/day in addition
to aspirin (Class I, Level of Evidence: B) (61). For
patients receiving a DES for a non-ACS indication,
clopidogrel 75 mg/day is indicated. The recently
updated European Society of Cardiology guidelines
are slightly different for patients with stable coronary
artery disease and recommend 1 month of DAPT after
BMS implantation, and 6 months of DAPT with aspirin
and clopidogrel after DES implantation (62). In
patients receiving a stent (BMS or DES) after ACS the
recommendation is 12 months of DAPT with aspirin
and ticagrelor or prasugrel (or clopidogrel when
ticagrelor and prasugrel are contraindicated) (63).
Ongoing large-scale trials are investigating the
safety and efﬁcacy of shorter or longer DAPT dura-
tions. Recently, several trials showed better out-
comes with a 3- to 6-month DAPT duration in rather
low-risk patients due to similar ischemic endpoint
but signiﬁcantly lower bleeding rates (64–66) Two
modestly sized trials, one comparing 12-month with
24-month DAPT duration and another comparing
6-month with 24-month DAPT duration, found no
differences in composite endpoints of adverse events,
with similar rates of stent thrombosis (66,67). An
even longer DAPT duration is under investigation in
the >20,000-patient DAPT Study (Dual Antiplatelet
Therapy study) that will determine whether DAPT
for 30 months compared with only 12 months may
protect against ST.
ADJUNCTIVE ANTITHROMBOTIC STRATEGIES
The role of the intravenous GPIs abciximab, tiroﬁban,
and eptiﬁbatide in the current era of oral DAPT is
unclear. In general, treatment with GPIs in ACS re-
duces acute ST compared with heparin alone (40,68).
In the HORIZONS-AMI trial (Harmonizing outcomes
with revascularization and stents in acute myocardial
infarction), which randomized 3,602 STEMI patients
undergoing primary PCI to treatment with bivalirudin
monotherapy or heparin plus a GPI, the use of biva-
lirudin was associated with an increased rate of acute
TABLE 4 Stent Thrombosis and Bleeding Rates in Trials Comparing Clopidogrel With Novel P2Y12 Inhibitors and Single-Dose
Versus Double-Dose Clopidogrel
Study (Ref. #) Year Follow-Up Comparison
Deﬁnite/Probable
Stent Thrombosis p Value
TIMI Major
Bleeding p Value
TRITON (53) 2007 15 months Clopidogrel 2.4 (142/6,422) <0.001 1.8 (111/6716) 0.03
Prasugrel 1.1 (68/6,422) 2.4 (146/6741)
PLATO (54) 2009 12 months Clopidogrel 2.9 (158/5,649) 0.009 7.7 (638/9186) 0.57
Ticagrelor 2.2 (118/5,640) 7.9 (657/9235)
CHAMPION (56) 2009 48 h Clopidogrel 0.3 (11/3,865) 0.34 0.3 (14/4365) 0.39
Cangrelor 0.2 (7/3,889) 0.4 (19/4374)
CHAMPION PHOENIX (52) 2009 48 h Clopidogrel 1.4 (74/5,469) 0.01 0.1 (5/5527) 0.99
Cangrelor 0.8 (46/5,470) 0.1 (5/5529)
CURRENT-OASIS 7 (55) 2010 30 days Clopidogrel 2.3* <0.001 0.7 (60/8703) 0.074
Double-dose clopidogrel 1.6* 1.0 (80/8560)
Values shown are % (n/N). *Number not reported.
TIMI ¼ Thrombolysis In Myocardial Infarction.
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1087ST (1.3% vs. 0.3%, p < 0.01) (40). Nonetheless, 30-day
and 1-year ST rates were similar in both treatment
arms, and bivalirudin reduced major bleeding and
mortality rates (40,69). The recent EUROMAX (Euro-
pean Ambulance Acute Coronary Syndrome Angiog-
raphy) trial randomized 2,218 STEMI patients who
were being transported for primary PCI to pre-
hospital administration of either bivalirudin or
unfractionated or low molecular weight heparin with
optional GPIs (39). Bivalirudin reduced major
bleeding (2.6% vs. 6.0%, p < 0.001) but still showed
higher acute ST (1.1% vs. 0.2%, p ¼ 0.007) than the
control arm.
TREATMENT FOR ST AND THE ROLE OF
INTRAVASCULAR IMAGING
The preferred treatment for ST is emergency PCI,
including the possibility of thrombus aspiration re-
storing antegrade blood ﬂow. Additional stent im-
plantation is not absolutely necessary and is advised
for treatment of signiﬁcant residual dissections.
Intravascular imaging with IVUS or OCT can provide
signiﬁcant insight into underlying mechanisms
causing this complication. Imaging can be safely per-
formed after initial stabilization of the patient. IVUS/
OCT can interrogate the entire arterial segment around
the stent and can identify several conditions that
can be largely undetectable by angiography. Addi-
tionally, OCT can visualize thrombus and stent
struts at a higher resolution than IVUS; however, fewer
clinical studies have used OCT, which requires addi-
tional intracoronary contrast injection to displace
blood and enable visualization, which may not be
aswell tolerated in hemodynamically compromised ST
patients.STENT UNDEREXPANSION. This is a common mech-
anism underlying ST. A rigid arterial segment has
severely restricted the expansion of the initially
implanted stent, or an undersized stent may have
been selected initially (Figure 3). If conﬁrmed by
IVUS/OCT, high-pressure balloon angioplasty with
noncompliant balloons sized according to the normal
adjacent reference segment can be attempted. A new
stent can be particularly deleterious in treating stent
underexpansion if the reason is due to a highly rigid
(e.g., calciﬁed) segment because multiple layers of
stent metal will be present in an underexpanded
lesion. If balloon expansion is ineffective, then the
patient should be temporarily treated with balloon
angioplasty and return for deﬁnite therapy after the
acute ST presentation has passed. Subsequent treat-
ment options may depend on the exact location of the
stent, the neighboring anatomy, and the experience
of the operator: 1) rotational atherectomy can ablate
the stent struts and the underlying calciﬁc plaque
(26,70); 2) excimer laser aiming at the unexpanded
area in combination with contrast dye infusion can
create local conditions that may ablate the problem-
atic strut as noted above (26,71); and 3) aortocoronary
bypass surgery can provide ﬂow distal to the stent
area, although it may not prevent recurrent throm-
bosis at the underexpanded area.
STENT MALAPPOSITION. This can be veriﬁed by the
existence of a space ﬁlled with blood between the
stent struts and the vessel wall (Figure 1). The extent
of this low-ﬂow area has been associated with ST
(42). Angioplasty with an appropriately sized balloon
as determined by the IVUS/OCT-derived measure-
ment of the arterial wall diameter at the culprit
cross sections typically sufﬁces to ameliorate this
problem.
FIGURE 3 Stent Underexpansion in a Patient Presenting With Late Stent Thrombosis of a Drug-Eluting Stent Placed in the LAD
Approximately 1 year after stent placement, this patient presented with an acute anterior ST-segment elevation myocardial infarction.
Emergency coronary angiography revealed a 90% hazy lesion within the LAD stent consistent with late stent thrombosis. (Left) Intracoronary
OCT revealed a large burden of irregularly contoured thrombus within the middle of the stent, also seen on the longitudinal OCT reconstruction
below at the 22-mm mark of the OCT pullback (arrowhead). As the stent struts are in contact with arterial wall, the stent is not malapposed in
this area. (Right) However, the OCT image of the immediate proximal ﬂanking artery at 26 mm demonstrates that the reference artery area and
diameter are substantially larger than within stented segment. This ﬁnding demonstrates stent underexpansion, which is a risk factor for stent
thrombosis. The patient was treated with OCT-guided appropriately sized percutaneous transluminal coronary angioplasty. LAD ¼ left anterior
descending artery; OCT ¼ optical coherence tomography.
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1088DISSECTIONS. Stent edge dissections can provoke ST
and are easily detectable by IVUS/OCT, despite being
sometimes dubious angiographically (72). A new
stent can typically cover them and restore adequate
ﬂow.
NEW PLAQUE RUPTURE. This condition essentially
means the absence of ST per se and supports the
extension of thrombosis within the stent after initia-
tion at the adjacent plaque disruption area. A new
stent may be needed to treat the culprit new lesion
area.
STENT FRACTURE. Right coronary artery lesions,
excessive tortuosity or angulation of the vessel,
overlapping stents, and longer stents have been
associated with an increased risk of stent fracture
(73). A stent fracture may cause mechanical damage
to the endothelium that could subsequently lead to
ST and can be treated with implantation of a short
stent to cover the area of the stent fracture.
NEGATIVE REMODELING AT THE STENT EDGE.
This can explain abrupt lumen compromise distal to a
stent that might have predisposed to ﬂow reduction.
NEOATHEROSCLEROSIS. The development of an ACS
caused by rupture or erosion of a neoatherosclerotic
plaque in a previously stented lesion has been
acknowledged as a potential culprit in very late ST(Figure 2) (74). Intracoronary imaging, particularly
OCT, is critical in detecting neoatherosclerosis
in vivo (75).
ST RISK ASSESSMENT AND PREVENTION
PATIENT, LESION, AND STENT SELECTION. As there
are a number of modiﬁable risk factors for the
development of ST, several preventive strategies may
decrease the risk of ST. Adequate patient and lesion
selection is a ﬁrst priority. Physicians may prefer to
use BMS in lesions with a low risk of restenosis and
in patients at increased risk of bleeding, scheduled
for surgery, allergic to thienopyridines, and/or in
whom compliance is questionable. After awareness
of very late ST was raised, novel DES types were
designed to provide superior safety and efﬁcacy
compared with ﬁrst-generation DES. As the durable
polymer on ﬁrst-generation DES was considered to
be associated with ST, newer DES designs include,
among others, the following: bioresorbable poly-
mers; biomimetic polymers; polymer coating on the
abluminal surface of stent struts only; and fully
biodegradable DES (76). A large-scale network meta-
analysis of 49 randomized trials revealed signiﬁ-
cantly lower ST rates with the “second-generation”
everolimus-eluting stent containing a ﬂuoropolymer
compared with other durable polymer DES as well as
TABLE 5 Integer-Based Risk Score for 1-Year Deﬁnite/Probable Stent Thrombosis in Patients With Acute Coronary Syndromes
Variable Integer Assignment for Stent Thrombosis Risk Score Calculation Add to Score
Type of acute coronary syndrome NSTE-ACS w/o ST changes þ1 NSTE-ACS with ST deviation þ2 STEMIþ4
Current smoking Yes: þ1 No: þ0
Insulin-treated diabetes mellitus Yes: þ2 No: þ0
History of PCI Yes: þ1 No: þ0
Baseline platelet count <250 K/ml: þ0 250 K/ml–400 K/ml: þ1 >400 K/ml: þ2
Absence of early (pre-PCI) Heparin* Yes: þ1 No: 0
Aneurysm or ulceration Yes: þ2 No: 0
Baseline TIMI ﬂow grade 0/1 Yes: þ1 No: 0
Final TIMI ﬂow grade <3 Yes: þ1 No: 0
No. of vessels treated 1 vessel: þ0 2 vessels: þ1 3 vessels: þ2
ST Risk Score
*Includes parenteral heparin or low molecular weight heparin.
PCI ¼ percutaneous coronary intervention; NSTE-ACS ¼ non-ST-segment elevation acute coronary syndrome; w/o ¼ without; other abbreviations as in Tables 2 to 4.
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1089BMS to 2-year follow-up (77). Two even larger
network meta-analyses, which also included data on
biodegradable polymer DES, one comprising 258,544
patients from 126 randomized trials (78) and another
comprising 63,242 patients from 60 randomized
trials (79), were recently published. These studies
conﬁrmed that newer generation durable polymer
stents such as the everolimus-eluting stent and the
Resolute zotarolimus-eluting stent (Medtronic,
Santa Rosa, California) provide the best combination
of safety and efﬁcacy even when compared with
biodegradable polymer DES. Fully bioabsorbable
coronary stents may reduce very late stent throm-
bosis, but long-term results of large-scale trials
investigating the safety and efﬁcacy of these devices
are not yet available.
RISK SCORE CALCULATION. A risk score has been
proposed to personalize risk assessment for the oc-
currence of ST in ACS patients (Table 5) (80). This risk
score may be used to identify patients who might
beneﬁt the most from more aggressive antiplatelet
therapy after stent implantation.
TECHNIQUE. An optimal procedural result is impor-
tant to minimize the risk of ST. Proper stent expan-
sion and apposition over the full length of the stent
should be ascertained, and residual dissections
should be avoided. A recent study by Roy et al.
(81) reported a strong trend toward reduced ST
after IVUS-guided stent implantation compared with
angiography only–guided PCI. As the risk of ST in-
creases with stent length, excessive use of stents is
discouraged. However, it is imperative that stents
do cover the entire lesion because residual plaque
at stent edges can also produce dissections, ﬂow
compromise, and ST. In bifurcation lesions, aprovisional side-branch stenting approach might be
preferable to routine crush and culotte stenting,
which have been associated with higher ST rates
(82,83). When a 2-stent (DES) approach is imple-
mented in a bifurcation, re-endothelialization can be
particularly slow and enhance ST risks.
DAPT COMPLIANCE AND INTERRUPTION. Compli-
ance with DAPT is paramount to minimize the risk of
ST (29,84), particularly if it occurs within 30 days of
implantation. Unclear communication of treatment
plans, low levels of patient education, and other
social factors have been shown to inﬂuence DAPT
compliance and should routinely be taken into
account.
Several studies suggested that the relationship
between ST and nonadherence to DAPT varies over
time. It is strongest in the ﬁrst month after stent
implantation, remains important until 6 months,
but fades afterward (85,86). The 5,031-patient PARIS
(Patterns of Non-adherence to Anti-platelet Re-
gimens in Stented Patients) registry investigated
different categories of DAPT cessation: physician-
recommended cessation, interruption (for surgery),
and disruption (abrupt, unsupervised nonadherence
or for bleeding) (86). At 2 years after stent implanta-
tion, overall DAPT cessation was 57.3%, discontinua-
tion occurred in 40.8%, interruption in 10.5%, and
disruption in 14.4% of patients. DAPT disruption
was associated with an increased risk of ST. This
effect was strongest during the ﬁrst 7 days after
DAPT cessation (hazard ratio: 18.25, p < 0.0001) and
weakened overtime.
RECOMMENDATIONS FOR DAPT INTERRUPTION.
When considering an elective invasive diagnostic
test or surgery in a patient with coronary stents, it
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1090may be preferable to postpone the procedure until
1 year after stent implantation. If there are pressing
reasons to interrupt DAPT before the guideline-
recommended period of 6 to 12 months, this should
be postponed as long as possible, and aspirin should
be continued.
CONCLUSIONS
ST is an uncommon but serious complication of PCI.
The incidence of early and late ST is similar in BMS
and DES, but very late ST, although uncommon,occurs more frequently in ﬁrst-generation DES. Many
risk factors for ST have been identiﬁed by intravas-
cular imaging and pathology, some modiﬁable and
some not. Adequate patient, lesion, and stent selec-
tion; a good technical result; and effective DAPT
are critical in minimizing the risk of ST.
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